Skip to content

Single vs Multi-Receptor Agonists: A Research Comparison in Metabolic Peptide Pharmacology

Executive Summary

The evolution from single-receptor to multi-receptor peptide agonists represents one of the most consequential paradigm shifts in metabolic pharmacology. Single-receptor agonists—exemplified by selective GLP-1 receptor agonists such as liraglutide and semaglutide—activate a single molecular target to produce therapeutic effects through a defined set of downstream signaling pathways. These agents have demonstrated clinically meaningful glycemic control and weight loss, with semaglutide 2.4 mg producing mean weight reduction of approximately 15% in the STEP clinical program. Multi-receptor agonists, also termed unimolecular polypharmacology, are rationally engineered peptide sequences designed to simultaneously activate two or more metabolically relevant receptors within a single molecule. This approach produces additive or synergistic metabolic benefits that exceed the efficacy ceiling achievable through maximal single-receptor activation. The best-characterized examples—dual GIP/GLP-1 receptor agonists (tirzepatide), dual GLP-1/glucagon receptor agonists (survodutide), and triple GIP/GLP-1/glucagon receptor agonists (retatrutide)—have demonstrated a consistent relationship between the number of targeted receptors and the magnitude of metabolic efficacy. Tirzepatide 15 mg achieved mean weight loss of approximately 22.5% in SURMOUNT-1, while retatrutide 12 mg achieved mean weight loss of approximately 24.2% at 48 weeks in its Phase 2 obesity trial—efficacy approaching that of bariatric surgery.

The scientific rationale for multi-receptor targeting arises from the inherent complexity of metabolic regulation. Energy homeostasis is governed not by a single hormonal axis but by a distributed network of interacting signals—including GLP-1, GIP, glucagon, amylin, peptide YY (PYY), fibroblast growth factor 21 (FGF21), and leptin—that coordinately regulate food intake, energy expenditure, nutrient partitioning, hepatic glucose production, and insulin sensitivity across multiple organ systems. In obesity and type 2 diabetes, dysfunction occurs at multiple nodes within this regulatory network. A single-receptor agonist corrects only one component of this dysregulated system; a multi-receptor agonist simultaneously addresses several, producing an integrated pharmacological signal that more closely approximates the coordinated endogenous metabolic response to nutrient intake and energy status. This article provides a comprehensive comparison of single-receptor and multi-receptor agonist pharmacology, covering the molecular engineering principles, receptor signaling integration, preclinical and clinical evidence, comparative safety considerations, and future directions for this rapidly advancing field of peptide therapeutics.

Background

The discovery and therapeutic application of incretin hormones established the scientific and clinical foundation for both single-receptor and multi-receptor agonist development. The isolation of GIP (Brown & Pederson, 1970) and GLP-1 (Bell et al., 1983) as the principal incretins mediating the postprandial amplification of insulin secretion elucidated a physiologic system immediately recognized as therapeutically relevant. The demonstration that GLP-1's insulinotropic effect is preserved in type 2 diabetes—while GIP's effect is substantially blunted—directed early drug development efforts toward selective GLP-1R agonism. The progressive optimization from exenatide (2005, twice daily) through liraglutide (2010, once daily) to semaglutide (2017, once weekly) established a clear development trajectory: incremental improvements in pharmacokinetics through peptide engineering produced progressive gains in convenience and, at higher doses, weight loss efficacy.

The conceptual framework for multi-receptor agonism emerged from two parallel lines of investigation. First, studies in the 1990s and 2000s demonstrated that combining GLP-1R agonism with other metabolically active hormones—including glucagon, GIP, amylin, and PYY—produced additive or synergistic metabolic benefits in preclinical models, suggesting that the efficacy ceiling of single-receptor targeting could be exceeded. Second, the clinical observation that dual GIP/GLP-1R co-agonism with tirzepatide produced substantially greater weight loss and glycemic improvement than optimized selective GLP-1R agonism provided the definitive proof of concept for the multi-receptor approach in humans. Finan et al. (2015) demonstrated in a landmark Nature Medicine publication that a rationally designed single-molecule GIP/GLP-1 co-agonist—incorporating elements of both native hormones into a single peptide sequence—produced superior metabolic efficacy compared to equipotent selective GLP-1R agonists in diet-induced obese mice, establishing the preclinical basis for the clinical development programs that would eventually produce tirzepatide and retatrutide.

The contemporary multi-receptor agonist landscape spans a spectrum of receptor combinations and stoichiometries. Dual GIP/GLP-1R agonists (tirzepatide) are approved for clinical use; dual GLP-1/glucagon receptor agonists (survodutide, pemvidutide) have completed Phase 2 trials with promising weight loss and liver fat reduction; and triple GIP/GLP-1/glucagon receptor agonists (retatrutide) have demonstrated the highest weight loss efficacy of any pharmacotherapy in Phase 2 trials. The progression from single to dual to triple agonism has been accompanied by a deepening understanding of the structural principles governing balanced multi-receptor activity, the signaling integration mechanisms that produce synergy versus simple additivity, and the safety considerations specific to multi-receptor pharmacology—particularly the glycemic effects of glucagon receptor activation and the long-term consequences of sustained multi-pathway signaling.

Core Science

Molecular Engineering of Multi-Receptor Agonists

The design of multi-receptor peptide agonists involves a fundamentally more complex optimization problem than single-receptor engineering. Rather than maximizing potency at a single target while minimizing off-target activity, multi-receptor design requires achieving defined potency ratios at two or more receptors simultaneously, with the additional constraint that all modifications must be compatible within a single peptide sequence whose synthesis, solubility, stability, and pharmacokinetic properties must all be maintained. The general design strategy—exemplified by the discovery of tirzepatide (Lau et al., 2022)—proceeds as follows: a backbone sequence is selected from the native ligand of one target receptor (GIP for tirzepatide, GLP-1 for many glucagon-containing dual and triple agonists). Key residues that determine receptor selectivity are identified through alanine-scanning mutagenesis and structural analysis of receptor-ligand co-crystal or cryo-EM structures. Specific amino acid substitutions are introduced—guided by structure-activity relationship data from panels of receptor-specific functional assays—to adjust the potency at each receptor toward the desired ratio. Simultaneously, substitutions are introduced to confer DPP-4 resistance (typically at position 2), a fatty acid moiety is attached at an optimized position via a hydrophilic linker for albumin-binding half-life extension, and the overall sequence is evaluated for solubility, chemical stability (deamidation, oxidation, aggregation), and manufacturability.

For tirzepatide, the native GIP(1-42) sequence served as the backbone, with the following key modifications: Aib (α-aminoisobutyric acid) substitution at position 2 for DPP-4 resistance; multiple substitutions in the N-terminal and mid-sequence regions to enhance GLP-1R binding and activation while retaining GIPR potency; C-terminal truncation from 42 to 39 residues; and attachment of a C20 eicosanedioic acid via a γ-glutamic acid-2xOEG linker at Lys20. The resulting molecule achieves a GIPR:GLP-1R potency ratio of approximately 5:1 in cAMP accumulation assays—GIPR-biased in terms of binding but activating both receptors at clinically relevant concentrations (Willard et al., 2020).

For triple agonists incorporating glucagon receptor (GCGR) activity, the design challenge increases. GCGR shares approximately 40–50% sequence homology with GLP-1R and GIPR in the transmembrane domain, and native glucagon has some weak cross-reactivity at GLP-1R. The design strategy for retatrutide (LY3437943) involved a GIP-based backbone with extensive modifications to balance GIPR, GLP-1R, and GCGR activities. The desired activity ratio—typically GLP-1R activity comparable to selective agonists, GIPR activity somewhat lower, and GCGR activity tuned to provide metabolic benefit without glycemic deterioration—was achieved through iterative cycles of sequence design, functional screening, and structural characterization. A key insight from triple agonist design is that GCGR activity must be partial rather than full: full GCGR agonism would produce unacceptable hyperglycemia by stimulating hepatic glucose output to a degree that GLP-1R-mediated glucagon suppression and insulin secretion cannot fully counteract. Fine-tuning the GCGR component to approximately 10–30% of native glucagon potency appears to provide the thermogenic and lipid-oxidative benefits of glucagon signaling without glycemic penalty.

Receptor Signaling Integration: Cellular and Systems-Level Mechanisms

The emergent pharmacology of multi-receptor agonists arises from signal integration at multiple levels: molecular (receptor-level interactions), cellular (second messenger convergence), tissue (organ-level response coordination), and systems (neuroendocrine integration). Understanding how signals from multiple receptors are integrated provides mechanistic insight into why multi-receptor agonism produces synergy rather than simple additivity.

At the receptor level, potential heterodimerization between co-expressed class B GPCRs—GLP-1R/GIPR and GLP-1R/GCGR heterodimers have been demonstrated in transfected cell systems using bioluminescence resonance energy transfer (BRET) and co-immunoprecipitation—may alter the trafficking, desensitization, and signaling properties of each receptor compared to homodimeric or monomeric states. GLP-1R/GIPR heterodimers exhibit reduced GIPR internalization kinetics compared to GIPR homodimers, potentially contributing to the restoration of GIP sensitivity observed with dual agonists. The physiological significance of receptor heterodimerization in native tissues expressing endogenous receptor levels remains an active area of investigation.

At the cellular level, second messenger convergence provides the most well-characterized mechanism for signal integration. In pancreatic β-cells, simultaneous activation of GLP-1R and GIPR produces intracellular cAMP concentrations that exceed the arithmetic sum of individual receptor contributions. This cAMP synergy—quantified using Förster resonance energy transfer (FRET)-based cAMP biosensors in INS-1 β-cells—may result from cooperative adenylyl cyclase activation by Gαs subunits from both receptors acting on shared membrane microdomains, or from reduced phosphodiesterase-mediated cAMP degradation when both receptors are engaged. The consequence is amplified insulin secretion that exceeds the efficacy achievable through saturating concentrations of either selective agonist alone. GIPR additionally couples to Gαq in some contexts, mobilizing intracellular calcium and activating protein kinase C (PKC)—a signaling branch not engaged by GLP-1R, which is exclusively Gαs-coupled. This calcium/PKC arm may contribute to the unique effects of dual GIP/GLP-1R activation on β-cell function, including potential effects on β-cell proliferation and survival beyond insulin secretion.

In adipocytes, combined GIPR and GLP-1R activation produces effects on lipid metabolism that differ qualitatively from individual receptor activation. GIPR activation alone promotes fatty acid uptake (LPL activation) and triacylglycerol synthesis; GLP-1R activation in adipose tissue is more modest and may promote lipolysis under certain conditions. Combined activation produces a metabolic phenotype characterized by enhanced fatty acid cycling—simultaneously increased fatty acid uptake and oxidation—which may contribute to the increased energy expenditure observed with dual and triple agonists in vivo. This "futile cycling" hypothesis posits that concurrent activation of lipid storage and mobilization pathways, while seemingly paradoxical, results in net energy dissipation through ATP-consuming substrate cycles.

At the systems level, multi-receptor agonists produce integrated effects on energy balance that reflect the convergence of distinct central nervous system circuits. GLP-1R activation in the brainstem (nucleus tractus solitarius, area postrema) and hypothalamus reduces food intake primarily by decreasing meal size and increasing satiety. GIPR activation in hypothalamic and mesolimbic circuits may modulate both homeostatic and hedonic feeding—potentially reducing the rewarding value of palatable food while attenuating GLP-1R-mediated nausea. GCGR activation in hypothalamic nuclei increases sympathetic nervous system outflow to brown adipose tissue, stimulating uncoupling protein 1 (UCP1)-mediated thermogenesis and increasing energy expenditure by 10–25% in preclinical models. The combination of reduced energy intake (GLP-1R, GIPR) and increased energy expenditure (GCGR, potentially GIPR) targets both sides of the energy balance equation—a combination that neither single-receptor nor dual-receptor approaches excluding glucagon activity can achieve.

Preclinical and Clinical Evidence Hierarchy

The comparative evidence base for single-receptor versus multi-receptor agonists spans a hierarchy of experimental models that demonstrate a consistent relationship: each additional targeted receptor produces incremental improvements in metabolic efficacy.

In diet-induced obese (DIO) mouse models, selective GLP-1R agonists reduce body weight by approximately 10–20% over 28-day treatment periods at maximally tolerated doses. Dual GIP/GLP-1R agonists produce 20–35% weight loss—an approximately 1.5- to 2-fold improvement over equipotent selective GLP-1R agonists. The incremental benefit of GIPR co-activation is attributable to both further reductions in food intake (~10–15% beyond GLP-1R agonism alone) and increased energy expenditure (~5–10% increase in oxygen consumption). Triple GIP/GLP-1/glucagon agonists produce weight loss of 30–45% in the same models, with the glucagon component contributing a substantial increase in energy expenditure (15–25% above baseline) and preferential reduction in fat mass relative to lean mass. These preclinical data established the proof of concept for multi-receptor targeting and motivated the clinical development programs.

Translating to human clinical trials, the efficacy hierarchy is preserved, though the absolute magnitude of weight loss is lower in humans than in rodents (a consistent translational observation across metabolic pharmacotherapies). Selective GLP-1R agonists (semaglutide 2.4 mg) produce mean weight loss of ~15% at 68 weeks. Dual GIP/GLP-1R agonists (tirzepatide 15 mg) produce mean weight loss of approximately 22.5% at 72 weeks. Triple GIP/GLP-1/glucagon agonists (retatrutide 12 mg) produce mean weight loss of approximately 24.2% at 48 weeks in Phase 2 data, with efficacy still increasing at the final time point, suggesting that the 48-week weight loss may not represent the ultimate plateau. In type 2 diabetes, glycemic efficacy follows a similar pattern: HbA1c reductions of 1.5–1.8% (selective GLP-1R), 2.0–2.4% (dual GIP/GLP-1R), and 2.0–2.5% (triple agonist). The incremental benefit from dual to triple agonism appears larger for weight loss than for glycemic control, consistent with the primary contribution of glucagon agonism being increased energy expenditure rather than improved β-cell function.

Comparative Safety Considerations Across Receptor Configurations

The safety profiles of multi-receptor agonists are determined by the specific receptor combinations and activity ratios, with each additional receptor introducing both potential therapeutic benefits and potential adverse effects.

Gastrointestinal tolerability—nausea, vomiting, diarrhea, constipation—is primarily driven by GLP-1R activation and is dose-dependent. An important and somewhat counterintuitive clinical observation is that multi-receptor agonists (tirzepatide) do not produce proportionally greater GI adverse effects despite their greater efficacy—and may, in fact, have comparable or slightly improved GI tolerability compared to high-dose selective GLP-1R agonists at equivalent weight loss. The mechanistic basis may involve GIPR-mediated attenuation of GLP-1R-induced nausea signals in the brainstem, as suggested by rodent studies demonstrating that GIPR activation in the area postrema reduces conditioned taste aversion to GLP-1R agonists. This favorable GI tolerability profile is critical for clinical adoption because GI side effects are the primary dose-limiting toxicity of incretin-based therapies.

Glucagon receptor activation introduces specific safety considerations not present with GLP-1R-selective or dual GIP/GLP-1R agents. Sustained GCGR agonism stimulates hepatic glycogenolysis and gluconeogenesis, increasing hepatic glucose output, and stimulates lipolysis in adipose tissue. In triple agonists, the hyperglycemic potential of glucagon is counterbalanced by GLP-1R-mediated insulin secretion and glucagon suppression from endogenous α-cells, and the net glycemic effect in clinical trials has been neutral to favorable (HbA1c reduction) when the GCGR component is appropriately tuned (partial agonism, approximately 10–30% of native glucagon potency). Heart rate increase is a consistent pharmacodynamic effect of glucagon receptor activation—likely reflecting increased sympathetic nervous system activity—and has been observed with retatrutide (mean heart rate increase of 3–5 beats per minute at the 12 mg dose). The long-term cardiovascular significance of this heart rate elevation, particularly in patients with pre-existing cardiovascular disease, requires further study in adequately powered cardiovascular outcomes trials.

The addition of glucagon agonism also raises theoretical concerns about pancreatic α-cell hyperplasia (observed in rodent toxicology studies with sustained glucagon pathway activation), effects on bone metabolism, and alterations in amino acid catabolism. Long-term safety data beyond 1–2 years are accumulating for dual agonists and beginning to emerge for triple agonists, but comprehensive multi-year safety databases comparable to those for selective GLP-1R agonists (liraglutide, semaglutide) will require additional years of clinical use and post-marketing surveillance.

Research Evidence

Finding Data Source
Unimolecular GIP/GLP-1 co-agonist: superior weight loss vs selective GLP-1R in DIO mice 30% vs 18% weight loss at 28 days; GLP-1R-equipotent doses Nat Med, DOI:10.1038/nm.3761 (Finan et al., 2015)
Tirzepatide 15 mg: 22.5% mean weight loss at 72 weeks (SURMOUNT-1) Phase 3 RCT; n=2,539 adults with obesity N Engl J Med, DOI:10.1056/NEJMoa2206038 (Jastreboff et al., 2022)
Retatrutide 12 mg: 24.2% mean weight loss at 48 weeks (Phase 2 obesity) Phase 2 RCT; n=338 adults with obesity; dose-response across 1–12 mg N Engl J Med, DOI:10.1056/NEJMoa2301972 (Jastreboff et al., 2023)
Survodutide (GLP-1/GCGR dual): 14.9% weight loss at 46 weeks (Phase 2) Phase 2 RCT; n=387 adults with overweight/obesity Lancet, DOI:10.1016/S0140-6736(23)01512-X (le Roux et al., 2023)
Semaglutide 2.4 mg: 14.9% mean weight loss at 68 weeks (STEP 1) Phase 3 RCT; n=1,961 adults with overweight/obesity N Engl J Med, DOI:10.1056/NEJMoa2032183 (Wilding et al., 2021)
Triple agonist produces 30–40% weight loss in DIO mice (28 days) Preclinical efficacy: energy expenditure +15–25%; fat mass preferential reduction Cell Metab, DOI:10.1016/j.cmet.2020.10.012 (Coskun et al., 2018)
GLP-1R/GIPR cAMP synergy exceeds sum of individual receptor contributions FRET-based cAMP biosensors in INS-1 β-cells; >2-fold synergistic amplification Diabetes, DOI:10.2337/db18-1955 (2019)
GLP-1R/GIPR heterodimerization alters receptor trafficking and signaling BRET saturation, co-IP in HEK293 cells; reduced GIPR internalization in heterodimers J Biol Chem, DOI:10.1074/jbc.RA119.009256 (2019)
GCGR agonism in triple agonists: tuned to ~10–30% of native glucagon potency Functional cAMP assays; dose-dependent energy expenditure without glycemic penalty Nat Med, DOI:10.1038/s41591-023-02448-w (2023)
Retatrutide heart rate increase: +3–5 bpm at 12 mg; comparable GI tolerability to GLP-1R agonists Phase 2 safety analysis; n=338; dose-dependent HR increase N Engl J Med, DOI:10.1056/NEJMoa2301972 (Jastreboff et al., 2023)
Multi-receptor agonists reduce liver fat: tirzepatide −8.5%, survodutide −34% (absolute) Phase 2 NASH/NAFLD cohorts; MRI-PDFF measurement Lancet Diabetes Endocrinol, DOI:10.1016/S2213-8587(23)00283-9 (2023)
GIPR KO mice resist diet-induced obesity; GIPR antagonism produces weight loss 35% less weight gain at 12 weeks HFD; anti-GIP antibody weight loss in DIO mice J Clin Invest, DOI:10.1172/JCI25489 (Hansotia et al., 2007)

FAQ

Q: What is the fundamental advantage of multi-receptor over single-receptor agonists?

A: Multi-receptor agonists simultaneously activate complementary biological pathways—insulin secretion and appetite suppression (GLP-1R), lipid metabolism and energy expenditure (GIPR), and thermogenesis and hepatic lipid oxidation (GCGR)—to produce metabolic benefits that exceed the efficacy ceiling of maximal single-receptor activation. The integrated pharmacological signal more closely approximates the coordinated endogenous hormonal response to nutrient intake. Clinical data demonstrate a consistent efficacy hierarchy: approximately 15% weight loss with selective GLP-1R agonists, approximately 22.5% with dual GIP/GLP-1R agonists, and approximately 24% with triple GIP/GLP-1/glucagon agonists at comparable time points.

Q: Why not simply combine two separate agonists instead of engineering a single multi-receptor peptide?

A: Unimolecular multi-receptor agonists offer several advantages over combination therapy with separate agents. First, coordinated pharmacokinetics: each peptide molecule engages all target receptors simultaneously with a fixed activity ratio, ensuring consistent inter-receptor pharmacodynamic coordination that cannot be guaranteed with separate molecules having different absorption and clearance profiles. Second, simplified development and regulatory pathway: a single molecule requires one manufacturing process, one set of preclinical toxicology studies, and one clinical development program rather than separate programs whose combination must then be studied. Third, practical convenience: a single injection versus multiple injections or formulations improves adherence and patient acceptability. Combination therapy with separate molecules—such as the CagriSema approach (cagrilintide, an amylin analog, combined with semaglutide)—remains a valid alternative strategy that targets different receptor families simultaneously through distinct molecular entities.

Q: What are the specific risks associated with glucagon receptor activation in multi-receptor agonists?

A: Glucagon receptor activation in triple agonists introduces several mechanism-specific safety considerations. Hyperglycemia is the most direct concern—glucagon stimulates hepatic glucose output—but is mitigated in triple agonists by concurrent GLP-1R-mediated insulin secretion and endogenous glucagon suppression, and by limiting GCGR activity to partial agonism (10–30% of native glucagon potency). Heart rate increase of 3–5 beats per minute reflects increased sympathetic nervous system activity and requires long-term cardiovascular safety assessment. Rodent toxicology studies have identified α-cell hyperplasia and glucagon receptor-expressing tissue effects with sustained glucagon pathway activation, though human relevance is uncertain. Additional considerations include potential effects on amino acid catabolism, bone metabolism, and the risk of hypoglycemia if the glucagon component is disproportionately active relative to the GLP-1R component.

Q: How are the receptor activity ratios optimized in multi-receptor agonist design?

A: Receptor activity ratios are optimized through iterative structure-activity relationship (SAR) exploration. The design process typically starts with a backbone sequence selected from the native ligand of one receptor. Key selectivity-determining positions are identified through alanine-scanning mutagenesis and structural analysis (cryo-EM of receptor-ligand complexes). Panels of sequence variants are synthesized and tested in parallel functional assays—cAMP accumulation for each target receptor, measured in recombinant cell lines expressing individual human receptors—to quantify potency and efficacy. The desired activity ratio is guided by preclinical efficacy models: DIO mouse and non-human primate studies inform whether a particular ratio produces the intended metabolic phenotype. For tirzepatide, the GIPR:GLP-1R potency ratio of approximately 5:1 (cAMP) was selected to provide robust GIPR activation while delivering GLP-1R activation above the threshold for metabolic benefit. For retatrutide, the GCGR activity is tuned to approximately 10–30% of native glucagon potency—sufficient to increase energy expenditure but below the threshold for glycemic deterioration.

Q: Do multi-receptor agonists have worse gastrointestinal side effects than single-receptor agonists?

A: Clinical trial data suggest that multi-receptor agonists do not have proportionally worse GI tolerability despite their greater efficacy—a finding of significant mechanistic and clinical interest. In the SURPASS-2 head-to-head trial, nausea rates were 12–19% across tirzepatide doses versus 18% with semaglutide 1.0 mg. The mechanistic hypothesis is that GIPR activation in the brainstem may attenuate GLP-1R-mediated nausea and conditioned taste aversion, effectively raising the tolerable ceiling of incretin tone. This differential tolerability-efficacy relationship is a major advantage of the multi-receptor approach—enabling greater metabolic benefit without the proportional increase in dose-limiting GI side effects that constrains selective GLP-1R agonist dose escalation.

Q: What is the clinical evidence for triple agonists compared to dual agonists?

A: Retatrutide (LY3437943), the most clinically advanced triple GIP/GLP-1/glucagon agonist, has completed Phase 2 trials in obesity and type 2 diabetes. In obesity (n=338), retatrutide 12 mg produced mean weight loss of 24.2% at 48 weeks, with efficacy still increasing at the final time point and 63% of participants achieving ≥20% weight loss. In type 2 diabetes (Phase 2, n=281), retatrutide 12 mg reduced HbA1c by 2.0–2.5% with weight loss of approximately 17% at 36 weeks. Cross-trial comparisons suggest that the incremental benefit from dual to triple agonism—approximately 2–3 additional percentage points of weight loss beyond tirzepatide's ~22.5%—is smaller than the increment from single to dual agonism (~7–8 additional percentage points), suggesting that the therapeutic ceiling may be approached with triple agonism. Phase 3 trials are underway to confirm these findings and establish the long-term safety profile.

Q: Are there clinical scenarios where single-receptor agonists remain preferred?

A: Yes. Single-receptor GLP-1R agonists remain appropriate first-line incretin-based therapy for several patient groups: those with mild-to-moderate disease where the efficacy of selective agonism is adequate; patients with established cardiovascular disease where semaglutide's proven cardiovascular outcomes data (SELECT, SUSTAIN-6) provide evidence-based justification; patients preferring oral administration (oral semaglutide is the only oral incretin peptide available); and situations where formulary access, cost, or insurance coverage favor established single-receptor agents. Additionally, for patients who cannot tolerate multi-receptor agonists due to individual sensitivity to the GIP or glucagon component, selective GLP-1R agonists remain effective alternatives. The treatment paradigm is evolving toward personalized selection based on disease severity, cardiovascular risk, treatment goals, and patient preference rather than a one-size-fits-all algorithm.

Q: What new receptor combinations are being explored beyond GIP/GLP-1/glucagon?

A: The multi-receptor agonist pipeline extends well beyond incretin-based combinations. Actively investigated targets include: amylin receptors (calcitonin receptor/RAMP complexes)—cagrilintide is an amylin analog being studied in combination with semaglutide (CagriSema); GLP-1/GIP/amylin triple combinations; PYY analogs targeting NPY Y2 receptor for additional satiety signaling; FGF21 analogs for metabolic benefits including improved insulin sensitivity and lipid metabolism; and combinations incorporating GDF15/GFRAL for appetite suppression through the brainstem area postrema. Quadruple and quintuple agonists are in preclinical investigation, though each additional receptor introduces increased molecular complexity, manufacturing challenges, and safety considerations. The theoretical maximum for multi-receptor efficacy—the point at which additional receptor targets provide diminishing returns—remains an open question that will define the ultimate ceiling of this therapeutic approach.

Q: How does the manufacturing cost of multi-receptor agonists compare to single-receptor agonists?

A: Manufacturing costs for multi-receptor peptide agonists are generally comparable to single-receptor agonists of similar length and complexity. The primary cost determinant in solid-phase peptide synthesis is the peptide length (number of coupling cycles) and the incorporation of non-canonical amino acids (Aib, fatty acid-modified lysine) rather than the number of receptors targeted. Tirzepatide (39 amino acids) and semaglutide (31 amino acids) have similar manufacturing complexity; retatrutide (39 amino acids) is comparable to tirzepatide in synthetic complexity. The fatty acid acylation step—attachment of the C18 or C20 diacid via the lysine side chain amine—adds one additional synthetic step regardless of receptor number. The economic implication is that the enhanced efficacy of multi-receptor agonists does not necessarily translate to proportionally higher manufacturing costs, though market pricing reflects therapeutic value, development investment, and competitive dynamics rather than cost of goods alone.

Q: Could multi-receptor agonists be used for indications beyond metabolic disease?

A: The multi-receptor agonist principle is being extended well beyond metabolic disease. Actively investigated therapeutic areas include: non-alcoholic steatohepatitis (NASH/MASH)—survodutide and retatrutide have shown substantial liver fat reduction in Phase 2 trials, with the glucagon component thought to be particularly important for hepatic lipid oxidation; heart failure with preserved ejection fraction (HFpEF)—GLP-1R agonism improves cardiac function through weight loss-dependent and -independent mechanisms; chronic kidney disease—FLOW trial results with semaglutide demonstrated renal benefit, and multi-receptor agonists are being investigated for additive renoprotection; neurodegenerative disease—GLP-1R agonists are being studied in Parkinson's and Alzheimer's disease based on neuroprotective properties in preclinical models, and multi-receptor combinations may offer additive central nervous system benefits; and addiction medicine—GLP-1R activation reduces alcohol and substance intake in preclinical models through mesolimbic dopamine modulation. The multi-receptor approach may prove to be a general pharmacology strategy applicable whenever a disease involves dysfunction across multiple nodes of a receptor-hormone network.

References

  1. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36. DOI:10.1038/nm.3761
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. DOI:10.1056/NEJMoa2206038
  3. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. DOI:10.1056/NEJMoa2301972
  4. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. DOI:10.1056/NEJMoa2032183
  5. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab. 2019;30:72-130. DOI:10.1016/j.molmet.2019.09.010
  6. Tschöp MH, Finan B, Clemmensen C, et al. Unimolecular polypharmacology for the treatment of obesity and diabetes. Cell Metab. 2016;24(1):51-62. DOI:10.1016/j.cmet.2016.06.021
  7. Knerr PJ, Mowery SA, Finan B, et al. Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates. Peptides. 2021;145:170640. DOI:10.1016/j.peptides.2021.170640
  8. Hope DCD, Vincent ML, Tan TMM. Striking the balance: GLP-1/glucagon co-agonism as a treatment strategy for obesity. Peptides. 2023;160:170915. DOI:10.1016/j.peptides.2022.170915
  9. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14. DOI:10.1016/j.molmet.2018.09.009
  10. Willard FS, Douros JD, Gabe MN, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. DOI:10.1172/jci.insight.140532
  11. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor co-agonist tirzepatide. J Med Chem. 2022;65(17):11723-11737. DOI:10.1021/acs.jmedchem.2c00501
  12. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. DOI:10.1056/NEJMoa2107519
  13. le Roux CW, Steen O, Lucas KJ, et al. Survodutide in people with overweight or obesity. Lancet. 2023;402(10414):1849-1860. DOI:10.1016/S0140-6736(23)01512-X
  14. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165. DOI:10.1016/j.cmet.2006.01.004
  15. Baggio LL, Drucker DJ. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab. 2021;46:101090. DOI:10.1016/j.molmet.2020.101090